Skip to main content

Advertisement

SpringerLink
Log in

Clinical Utility of Serum Tumor Markers and Circulating Tumor Cell Assays in the Treatment of Breast Cancer

  • Breast Cancer (Carla I. Falkson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Though serum tumor markers and circulating tumor cells (CTCs) have been available to the oncologist for many years, their place in the management of breast cancer remains unclear. Due to issues with sensitivity and specificity, tumor markers are unreliable for the detection of metastases in early stage breast cancer. For patients with metastatic breast cancer without measurable disease (e.g., bone-only disease, pleural effusions, or ascites), it is reasonable to obtain baseline values of serum tumor markers and attempt to correlate them with the first set of scans. In patients with elevated markers at baseline whose tumor marker levels decrease in correlation with an improvement in clinical symptoms, it may be reasonable to use them in conjunction with imaging to help determine whether there is progression of disease. CTCs have been found to hold strong prognostic value for breast cancer in both the early stage and metastatic settings. No large prospective studies to date, however, have shown any predictive value for CTCs and their clinical utility is therefore limited. Whether changing treatment in response to an increase in CTCs without radiologic progression results in improvements in quality of life or survival remains to be seen. CTCs hold great promise in the management of breast cancer and future studies will help delineate their role more appropriately.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.

    Article  PubMed  Google Scholar 

  2. Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602.

    Article  PubMed  CAS  Google Scholar 

  3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  PubMed  CAS  Google Scholar 

  4. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119:551–8.

    Article  PubMed  Google Scholar 

  5. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–57.

    Article  PubMed  CAS  Google Scholar 

  6. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874–85.

    Article  PubMed  CAS  Google Scholar 

  7. Price MR, Rye PD, Petrakou E, et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17–23, 1996. Tumour Biol. 1998;19 Suppl 1:1–20.

    Article  PubMed  Google Scholar 

  8. Chan DW, Beveridge RA, Muss H, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol. 1997;15:2322–8.

    PubMed  CAS  Google Scholar 

  9. Emens LA, Davidson NE. The follow-up of breast cancer. Semin Oncol. 2003;30:338–48.

    Article  PubMed  Google Scholar 

  10. Nicolini A, Tartarelli G, Carpi A, et al. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer. 2006;6:269.

    Article  PubMed  Google Scholar 

  11. Valenzuela P, Mateos S, Tello E, Lopez-Bueno MJ, Garrido N, Gaspar MJ. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur J Gynaecol Oncol. 2003;24:60–2.

    PubMed  CAS  Google Scholar 

  12. Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res. 2001;7:2357–62.

    PubMed  CAS  Google Scholar 

  13. Molina R, Zanon G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36:41–8.

    Article  PubMed  CAS  Google Scholar 

  14. Jager W, Kramer S, Palapelas V, Norbert L. Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest Suppl. 1995;221:87–92.

    Article  PubMed  CAS  Google Scholar 

  15. Molina R, Auge JM, Farrus B, et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem. 2010;56:1148–57.

    Article  PubMed  CAS  Google Scholar 

  16. Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer. 2002;38:1189–93.

    Article  PubMed  CAS  Google Scholar 

  17. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.

    Article  PubMed  CAS  Google Scholar 

  18. Cheung KL, Evans AJ, Robertson JF. The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat. 2001;67:273–8.

    Article  PubMed  CAS  Google Scholar 

  19. Kurebayashi J, Nishimura R, Tanaka K, et al. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study. Breast Cancer. 2004;11:389–95.

    Article  PubMed  Google Scholar 

  20. Tampellini M, Berruti A, Bitossi R, et al. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat. 2006;98:241–8.

    Article  PubMed  CAS  Google Scholar 

  21. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat. 1998;52:239–59.

    Article  PubMed  CAS  Google Scholar 

  22. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer. 1990;65:193–9.

    Article  PubMed  CAS  Google Scholar 

  23. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res. 1999;5:1950–60.

    PubMed  CAS  Google Scholar 

  24. Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13:920–8.

    Article  PubMed  CAS  Google Scholar 

  25. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.

    Article  PubMed  CAS  Google Scholar 

  26. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–24.

    Article  PubMed  CAS  Google Scholar 

  27. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420–30.

    Article  PubMed  Google Scholar 

  28. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer. 2008;113:2422–30.

    Article  PubMed  Google Scholar 

  29. Giuliano M, Giordano A, Jackson S, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011;13:R67.

    Article  PubMed  Google Scholar 

  30. Bidard F, Hajage D, Bachelot T, Andre F, Brain EG, Campone M, Dieras V, Asselain B, Mathiot C, Pierga J. Circulating tumor cells and Cyfra 21-1 as outcome-associated biomarkers In First Line Metastatic Breast Cancer: Results Of The Ic 2006-04 Study. Ann Oncol. 2011;22. This is the first prospective study of patients with metastatic breast cancer with CTC-associated outcome as the primary endpoint; CTC counts were correlated with overall survival.

  31. Rack B, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, et al. Use of Circulating Tumor Cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol. 2010;28. This is the largest study examining the prognostic value of CTCs before and after adjuvant chemotherapy in early stage breast cancer.

  32. Rack B, Schindlbeck C, Andergassen U, Schneeweiss A, Zwingers T, Lichtenegger W, et al. Use of Circulating Tumor Cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial. J Clin Oncol. 2010;28.

  33. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14:7004–10.

    Article  PubMed  CAS  Google Scholar 

  34. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16:2634–45.

    Article  PubMed  CAS  Google Scholar 

  35. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403–9.

    Article  PubMed  CAS  Google Scholar 

  36. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27:3303–11.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave., 777 PRB, Nashville, TN, 37212, USA

    Vandana G. Abramson MD & Ingrid A. Mayer MD

Authors
  1. Vandana G. Abramson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingrid A. Mayer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vandana G. Abramson MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abramson, V.G., Mayer, I.A. Clinical Utility of Serum Tumor Markers and Circulating Tumor Cell Assays in the Treatment of Breast Cancer. Curr. Treat. Options in Oncol. 12, 403–411 (2011). https://doi.org/10.1007/s11864-011-0164-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0164-2

Keywords

Search

Navigation